Investor Alert

New York Markets Close in:

Topics

Medicine and Health

Video

FDA Authorizes Merck's Covid-19 Pill: Here's How It Works

  • FDA Authorizes Merck's Covid-19 Pill: Here's How It Works FDA Authorizes Merck's Covid-19 Pill: Here's How It Works 5:55
    Pfizer's Fight Vs. Covid & Cancer Pfizer's Fight Vs. Covid & Cancer 2:07
    Health Care Solutions | The Wealth Gap Health Care Solutions | The Wealth Gap 23:55
2:20 a.m. Nov. 16, 2021 - By Ciara Linnane
UPDATE: Pfizer to allow generics companies to make its COVID-19 oral antiviral treatment, expand access to poorer countriesPfizer Inc. said Tuesday it has signed a voluntary license agreement with United Nations-backed public health organization the Medicines Patent Pool that will allow generics makers to manufacture its COVID-19 oral antiviral treatment. The move will help expand access to the drug to low and middle-income countries. Under the terms of the main license agreement, qualified generic medicine manufacturers worldwide that are granted sub-licenses "will be able to supply PF-07321332 in combination with ritonavir to 95 countries, covering up to approximately 53% of the world's population," the company said in a statement. "This includes all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa as well as countries that have transitioned from lower-middle to upper-middle-income status in the past five years. " Pfizer will not receive royalties on sales in those countries and will also waive royalties on sales in all countries covered by the agreement as long as COVID remains classified as a Public Health Emergency of International Concern by the World Health Organization. Pfizer said last week it would seek an emergency-use authorization for the treatment "as soon as possible." The company released data from a double-blind Phase 2/3 clinical trial in 1,219 unvaccinated adults with COVID-19 who were at high risk of severe disease and found it reduced the risk of dying or ending up in the hospital by 89%. Less than 1% of the patients who took the drug were hospitalized by the 28-day mark, compared with the 7% who received the placebo and were hospitalized or died. Participants took two pills a day for five days. Antivirals are expected to become a game changer in the pandemic, as they can be taken at home, while the current treatments are done by infusion in a clinical setting. Pfizer shares were down 0.7% premarket but have gained 35% in the year to date, while the Dow Jones Industrial Average has gained 18% and the S&P 500 has gained 25%.
2:41 a.m. Nov. 8, 2021 - By Jaimy Lee
Regeneron says its COVID-19 antibody cocktail can prevent COVID-19 infections for months Shares of Regeneron Pharmaceuticals Inc. gained 3.7% in premarket trading on Monday after the company said four subcutaneous injections of its monoclonal antibody treatment protected unvaccinated people from contracting COVID-19 by 81.6% for up to eight months. Four infusions of the treatment are considered one dose. "These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised," Dr. Myron Cohen, a physician in charge of the National Institutes of Health's work on monoclonal antibodies, said in a news release. Regeneron has already shared similar data in a published in the New England Journal of Medicine but this is a new analysis of that data, which came from a trial assessing giving the treatment to one household member if another was sick to see if it could prevent testing positive for the virus. The results came from 1,684 people who participated in the Phase 3, randomized, placebo-controlled trial. Regeneron's therapy is currently authorized as a treatment for people who are at high risk of severe disease and post-exposure prophylaxis for high-risk people who have been exposed to the virus. Regeneron's stock is up 26.6% so far this year, while the broader S&P 500 has gained 25.1%.
5:50 a.m. Oct. 13, 2021 - By Jaimy Lee
Progenity's stock is up 4.9% after securing four patents for ingestible technologiesShares of Progenity Inc. gained 4.9% in trading on Wednesday after the company said it received four patents from the U.S. Patent and Trademark Office related to its ingestible technologies that can be used to deliver medicine to the gastrointestinal tract. Progenity's stock has tumbled 56.0% so far this year, while the S&P 500 is up 15.8%.
1:29 a.m. Oct. 11, 2021 - By Ciara Linnane
Coronavirus tally: Global cases of COVID-19 near 238 million as Merck sees FDA approval for antiviralThe global tally for the coronavirus-borne illness climbed above 237.9 million on Monday, while the death toll rose above 4.85 million, according to . The U.S. continues to lead the world with a total of 44.3 million cases and 713,350 deaths. The U.S. is again averaging 2,000 deaths a day, , although new cases and hospitalizations are declining. Merck & Co. Inc. submitted an application for Emergency Use Authorization (EUA) with the Food and Drug Administration for molnupiravir, their oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults. The company had disclosed that data from a Phase 3 trial found the treatment reduced the risk of of hospitalization or death in adults at risk for progressing to severe COVID-19 by 50%. India is second by cases after the U.S. at 33.9 million and has suffered 450,782 deaths. Brazil has second highest death toll at 601,011 and 21.6 million cases. In Europe, Russia has most fatalities at 213,522, followed by the U.K. at 138,139.
1:12 a.m. Oct. 11, 2021 - By Tomi Kilgore
Merck, Ridgeback submit EUA application for their pill to treat COVID-19 Merck & Co. Inc. and Ridgeback Biotherapeutics said Monday that Merck has submitted an application for Emergency Use Authorization (EUA) with the Food and Drug Administration for molnupiravir, their oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults. The companies said the application followed positive results from a Phase 3 trial which showed that with adults at risk for progressing to severe COVID-19, molnupiravir reduced the risk of hospitalization or death by 50%. The companies said 7.3% (28 of 385) of those who received molnupiravir were hospitalized and there were not deaths after 29 days, while 14.1% of patients treated with a placebo (53 of 377) were hospitalized and there were eight deaths. "The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data," said Merck Chief Executive Robert Davis. Merck's stock, which fell 1.2% in premarket trading, has gained 3.4% year to date, while the Dow Jones Industrial Average has advanced 13.5%.
2:46 a.m. Oct. 4, 2021 - By Tomi Kilgore
OpGen stock rockets after upbeat revenue updateShares of OpGen Inc. rocketed 31.9% in active premarket trading Monday, after the precision medicine company provided a revenue update following the recent Food and Drug Administration clearance of its Acuitas AMR Gene Panel to aid in the diagnosis of severe infections. Trading volume spiked to 5.1 million shares ahead of the open, compared with the full-day average of about 1.8 million shares. The company said preliminary third-quarter revenue was approximately $1.2 million, compared with the FactSet consensus of $800,000. The stock has rallied 35.3% year to date through Friday, while the S&P 500 has gained 16.0%.
2:41 a.m. Sept. 30, 2021 - By Ciara Linnane
AstraZeneca vaccine shows 74% efficacy in large Phase 3 trial in U.S., Chile and Peru: NJEMThe COVID-19 vaccine developed by AstraZeneca PLC and Oxford University showed 74% efficacy at preventing symptomatic illness in a large late-stage trial conducted in the U.S., Chile and Peru, The Phase 3 trial involved 32,451 participants and sought to determine the vaccine's efficacy in preventing symptomatic illness measured 15 days after the second dose. The AstraZeneca vaccine has been widely used in the U.K. and Europe but is not yet authorized in the U.S. The data showed the vaccine had an 83.5% estimated efficacy in participants aged 65 or older. It proved safe with no serious adverse events and local and systemic reactions were generally mild or moderate, said the NJEM. The trial was conducted in collaboration with the Department of Health and Human Services and the National Institutes of Health.
10:03 a.m. Aug. 17, 2021 - By Jaimy Lee
Roche says arthritis drug authorized to treat hospitalized COVID-19 patients is in short supply Roche Holding AG said Monday that Actemra, its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short supply and will be so for weeks or months. The drug "has been widely used to treat hospitalized patients with severe or critical COVID-19 around the world, and demand for this medicine has increased to unprecedented levels globally," the company said. Demand for Actemra in the U.S., where the delta variant is behind the recent surge in cases and hospitalizations, is "well beyond 400% of pre-COVID levels over the last two weeks alone," according to Roche, which cited manufacturing limits, supply constraints, and the labor-intensive process of developing biologic drugs as reasons for the shortage. Roche's stock is up 15.6% so far this year, while the broader S&P 500 has gained 19.2%.
2:49 a.m. July 23, 2021 - By Tomi Kilgore
SOPHiA Genetics set to go public at a $1.1 billion valuationSOPHiA Genetics SA is set up for a public debut Friday, as the Switzerland-based data-driven medicine company's initial public offering price overnight at $18 a share, which was in the middle of the expected range of between $17 and $19 a share. The company sold 13.0 million shares in the IPO to raise $234 million, with the IPO pricing valuing the company at about $1.14 billion. The stock is expected to begin trading some time after the open on the Nasdaq under the ticker symbol "SOPH." J.P. Morgan, Morgan Stanley, Cowen and Credit Suisse are the joint book-running managers. The company recorded a net loss of $39.3 million on revenue of $28.4 million in 2020, after a loss of $33.8 million on revenue of $25.4 million in 2019. The company is going public at a time that the Renaissance IPO ETF has lost 1.0% over the past three months while the S&P 500 has gained 4.5%.
4:12 a.m. July 16, 2021 - By Joseph Walker
Cleveland Clinic, Mount Sinai and Providence won’t give Biogen’s new Alzheimer’s drug The three hospital operators are holding off on administering Aduhelm amid a debate over its effectivenessThree large hospitals are declining to administer Biogen Inc.’s new Alzheimer’s treatment, Aduhelm, the latest rupture to emerge from the Food and Drug Administration’s controversial approval of the drug last month.
3:54 a.m. July 16, 2021 - By Joseph Walker
Cleveland Clinic, Mount Sinai and Providence won’t give Biogen’s new Alzheimer’s drug The three hospital operators are holding off on administering Aduhelm amid a debate over its effectivenessThree large hospitals are declining to administer Biogen Inc.’s new Alzheimer’s treatment, Aduhelm, the latest rupture to emerge from the Food and Drug Administration’s controversial approval of the drug last month.
8:48 a.m. July 15, 2021 - By Tomi Kilgore
Teleflex stock tumbles toward 8-month low, paces S&P 500 declinersShares of Teleflex Inc. tumbled 10.9% toward an 8-month low in afternoon trading Thursday, enough to pace the S&P 500 decliners, and to put them on track for the biggest one-day percentage selloff since March 2020. Teleflex is a medical technology company, with products in the fields of urology, cardiac and respiratory care and emergency medicine. The company's UroLift System, which the company has recently said was one of its "key growth drivers," is a minimally invasive treatment for lower urinary tract symptoms resulting from benign prostatic hyperplasia. Chief Financial Officer Thomas Powell had said at UBS Global Healthcare Conference in May that he expected UroLift to show continued recovery after the COVID-19 pandemic weighed heavily on non-COVID-related procedures. Meanwhile, the Centers for Medicare & Medicaid Services' new anticipates 1% decline in clinical labor pricing for urology. The company did not immediately respond to a request for comment. The stock has now lost 9.7% year to date, while the SPDR Health Care Select Sector ETF has climbed 13.1% and the S&P 500 has advanced 15.7%.
4:04 a.m. July 1, 2021 - By Jaimy Lee
Novavax's experimental COVID-19 shot has 86.4% efficacy against the Alpha variantShares of Novavax Inc. were up 2.5% in premarket trading on Thursday, the day after The New England Journal of Medicine published a looking at how Novavax's COVID-19 vaccine candidate performed in a Phase 3 clinical trial conducted in 15,000 participants in the U.K. An earlier analysis of the data was previously published as a preprint. According to the new study, Novavax's experimental vaccine has an overall efficacy rate of 96.4% against the original strain of the virus and an 86.3% efficacy rate against the Alpha variant, which was first identified in the U.K. and has been the most dominant form of the virus in many countries since the start of the year. Novavax did not mention the Delta variant, which is now the most dominant form of the virus in the U.K., in this study. The company is conducting separate studies of its experimental shot in the U.S. Novavax's stock is up 90.4% for the year, while the broader S&P 500 has gained 14.4%.
11:57 a.m. June 25, 2021 - Barrons.com
Pfizer's Fight Vs. Covid & CancerAlbert Bourla, Pfizer's chairman & CEO, speaks with Jack Hough on the Streetwise podcast about the future of Covid booster shots as well as crucial cancer research and pursuing new breakthroughs in medicine.
4:28 a.m. June 23, 2021 - By Jaimy Lee
Study: There were at least 17 million undiagnosed COVID-19 cases in the U.S. through July 2020There were likely up to 17 million undiagnosed cases of COVID-19 in the U.S. through July 2020, based on new research that says the number of COVID-19 cases in the U.S. most likely exceeded the number of reported cases. The National Institutes of Health said Wednesday that for every 1 diagnosed case of COVID-19, there were 4.8 undiagnosed cases during the first six months of the pandemic in the U.S. This is thought to include many of the asymptomatic cases that contributed to the spread of the virus. The results came from a cohort of about 8,000 people who submitted blood samples for antibody analysis as part of the NIH SARS-CoV-2 Seroprevalence Project. The was published Tuesday in Science Translational Medicine.
3:40 a.m. June 22, 2021 - By Jaimy Lee
New research says Pfizer and Moderna's mRNA vaccines don't affect sperm parametersNew published in JAMA found there was no difference in sperm parameters in 45 men who received mRNA vaccines against COVID-19. The two authorized mRNA vaccines, which were developed by Pfizer Inc. and Moderna Inc. , are the most commonly utilized COVID-19 vaccines in the U.S. Researchers at the University of Miami Miller School of Medicine say they initiated the study after hearing concerns from some people that the vaccines could impact fertility. They noted the study has some limitations, given that the number of men enrolled in the study is a small sample size, and semen analysis is "an imperfect predictor of fertility potential." Back in April, concerns about fertility were cited as a top reason to avoid COVID-19 vaccination, , with 42% of adults between the ages of 18 and 29 saying they have heard the shots can cause infertility and 5% saying they believe this is true.
7:05 a.m. June 6, 2021 - By Quentin Fottrell
A new study links this popular diet with lower blood pressure — and reduced cardiac injury and strain ‘Our study represents some of the strongest evidence that diet directly impacts cardiac damage, and our findings show that dietary interventions can improve cardiovascular risk factors’‘Our study represents some of the strongest evidence that diet directly impacts cardiac damage, and our findings show that dietary interventions can improve cardiovascular risk factors.’
9:12 a.m. June 5, 2021 - By Quentin Fottrell
Two signs of COVID-19 that predict higher mortality are ‘easily measured’ at home ‘These findings apply to the lived experience of the majority of patients with COVID-19: being at home, feeling anxious, wondering how to know whether their illness will progress’‘These findings apply to the lived experience of the majority of patients with COVID-19: being at home, feeling anxious, wondering how to know whether their illness will progress.’
2:29 a.m. June 2, 2021 - By Jaimy Lee
Moderna signs deal to provide up to 466 million doses of its COVID-19 shot to UnicefShares of Moderna Inc. were down 0.2% in premarket trading on Wednesday after it announced a deal with Unicef to supply 34 million doses of its COVID-19 vaccine in the fourth quarter of 2021 and up to 466 million doses of its mRNA shot in 2022. Moderna's stock is up 76.7% for the year, while the broader S&P 500 has gained 11.8%. Results from the second interim analysis of the NIH-led Phase 1 study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age groups were published on September 29 in The New England Journal of Medicine. On November 30, 2020, Moderna announced the primary efficacy analysis of the Phase 3 study of the vaccine conducted on 196 cases. On November 30, 2020, the Company also announced that it filed for Emergency Use Authorization with the U.S.FDA and a Conditional Marketing Authorization (CMA) application with the European Medicines Agency. On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has also received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, the Philippines, Thailand, Brunei, Paraguay, Japan, South Korea and an Emergency Use Listing (EUL) from the World Health Organization (WHO). Initial data from Moderna's Phase 2 study in the U.S. showed that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351 (first identified in South Africa) and P.1 (first identified in Brazil). A booster dose of mRNA-1273.351, the Company's strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273. Safety and tolerability profiles following third dose booster injections of 50 µg of mRNA-1273 or mRNA-1273.351 were generally comparable to those observed after the second dose of mRNA-1273 in the previously reported Phase 2 and Phase 3 studies. A manuscript describing these preliminary results was submitted as a preprint to medRxiv and will be submitted for peer-reviewed publication upon completion of the multivalent mRNA-1273.211 booster arm. About Moderna
1:55 p.m. May 29, 2021 - By Alessandra Malito
I’m 52, won’t live past 80 and have $1.6 million. ‘I am tired of both the rat race and workplace politics.’ Should I retire? Have a question about retirement, including where to retire? Email HelpMeRetire@marketwatch.com Have a question about retirement, including where to retire? Email HelpMeRetire@marketwatch.com
9:32 a.m. May 18, 2021 - By Ciara Linnane
Acute care telemedicine provider SOC Telemed files for secondary offeringSOC Telemed Inc. , a provider of acute care telemedicine services and technology to U.S. hospitals and healthcare systems, filed for a secondary offering on Tuesday. Credit Suisse, William Blair and Guggenheim Securities are underwriting the deal. Proceeds will be used to repay debt and for general corporate purposes. "We provide technology-enabled clinical solutions, which include acute teleNeurology, telePsychiatry, teleCritical Care (ICU), telePulmonology, teleCardiology, teleInfectious Disease, teleMaternal-Fetal Medicine, teleNephrology, teleEndocrinology and other specialties," the company says in its filing documents. It had a pro forma loss of $16.7 million in the three months through March and revenue of $22.8 million.
7:26 a.m. May 16, 2021 - By Quentin Fottrell
Is it ethical for cruise lines, venues, schools or Broadway to restrict entry to people not vaccinated against COVID-19? Are vaccine holdouts ‘pathologically narcissistic’ or exercising their civil rights? And do private businesses have the right to refuse them? The Moneyist weighs inAre vaccine holdouts ‘pathologically narcissistic’ or exercising their civil rights? And do private businesses have the right to refuse them? The Moneyist weighs in.
2:01 a.m. May 4, 2021 - By Tomi Kilgore
Pfizer beats earnings expectations and lifts guidance, as COVID-19 revenue outlook increases 73%Shares of Pfizer Inc. jumped 1.6% toward a near five-month high in premarket trading Tuesday, after the drug giant beat earnings expectations and raised its full-year outlook, as revenue expectations for its COVID-19 vaccine jumped 73%. Net income rose to $4.88 billion, or 86 cents a share, from $3.36 billion, or 60 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share increased to 93 cents from 63 cents, and beat the FactSet consensus of 77 cents. Revenue grew 45% to $14.58 billion, above the FactSet consensus of $13.54 billion. Vaccine revenue tripled, to $4.89 billion from $1.61 billion, while oncology revenue rose 18% to $2.86 billion and internal medicine revenue grew 11% to $2.59 billion. For 2021, the company raised its guidance ranges for adjusted EPS to $3.55 to $3.65 from $3.10 to $3.20 and for revenue to $70.5 billion to $72.5 billion from $59.4 billion to $61.4 billion, as revenue expectations for the COVID-19 vaccine (BNT162b2) increased to $26 billion from $15 billion. The revenue projection for BNT162b2 includes guidance for 1.6 billion doses expected to be delivered this year. The stock, which is on track to open at the highest prices seen since mid-December, has gained 8.2% year to date through Monday, while the S&P 500 has advanced 11.6%.
6:13 a.m. May 3, 2021 - By Jaimy Lee
Pfizer says it submitted application for COVID-19 vaccine to Indian regulators 'months ago'Shares of Pfizer Inc. gained 2.2% in trading on Monday after the pharmaceutical company said it will donate $70 million in medicine to India, which is facing the worst surge in COVID-19 cases worldwide during the pandemic. The drugmaker also reiterated that the COVID-19 vaccine it developed with BioNTech SE has not yet been approved in India, though the application was "submitted months ago." "We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country," Pfizer CEO Albert Bourla wrote in a letter on Monday. As part of the donation to India, Pfizer will provide common treatments for COVID-19, including steroids and anticoagulants, as well as antibiotics for secondary bacterial infections. It will also provide funding for ventilators and oxygen concentrators. Pfizer's stock is up 7.3% for the year, while the broader S&P 500 has gained 11.3%.
8:28 p.m. April 18, 2021 - By Quentin Fottrell
The public’s expectation of perfection: Risk of blood clot from Johnson & Johnson COVID-19 vaccine is 0.00009% ‘It’s the same perceptual problem when we blindly drive to the airport texting, yet worry about the airplane’‘It’s the same perceptual problem when we blindly drive to the airport texting, yet worry about the airplane.’
10:48 a.m. April 15, 2021 - By Jaimy Lee
Merck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patientsShares of Merck & Co. were up 0.1% in premarket trading on Thursday after the drug company said the oral antiviral COVID-19 treatment it is developing with Ridgeback Biotherapeutics did not help hospitalized patients in a mid-stage clinical trial. The companies now plan to test molnupiravir in non-hospitalized COVID-19 patients in a Phase 3 trial, with plans to file for emergency authorization in the second half of the year. They are also planning to see if the experimental therapy works for post-exposure prophylaxis. In a separate news release, Merck said it is discontinuing MK-7110 as a treatment for patients hospitalized with COVID-19, saying that the Food and Drug Administration's request for additional clinical information would push the launch into 2022. "Merck is now focusing its efforts on advancing molnupiravir, which, as an oral medicine for outpatient use, represents a promising potential new approach, and on accelerating production of Johnson & Johnson's COVID-19 vaccine," Dr. Roy Baynes, chief medical officer for Merck Research Laboratories, said in the release. Merck's stock has gained 6.6% since the start of the year, while the broader S&P 500 is up 9.8%.
4:58 a.m. April 11, 2021 - By Quentin Fottrell
Weary of #fakenews, more Americans are getting their COVID-related news from peer-reviewed medical journals Social media doesn’t help people differentiate what is real from what is fake, but this class of publications mightSocial media doesn’t help people differentiate what is real from what is fake, but this class of publications might.
8:14 a.m. April 6, 2021 - By Jaimy Lee
Research letter indicates that Moderna's COVID-19 vaccine has efficacy past 6 months Shares of Moderna Inc. gained 5.9% in trading on Tuesday after published in The New England Journal of Medicine indicates that the company's COVID-19 vaccine generated antibodies that extend at least six months after the second dose among a small group of study participants. This is based on tracking COVID-19 antibodies in 33 participants in the Phase 1 clinical trial, which is still ongoing. This is a to data recently released about immune response to BioNTech SE and Pfizer Inc.'s mRNA vaccine. "Our data show antibody persistence," the researchers wrote in the letter, which published Tuesday. At this time it is unknown how long the vaccines protect people who have been immunized. Shares of Moderna have gained 17.5% since the start of the year, while the broader S&P 500 is up 8.6%.
4:34 a.m. April 3, 2021 - By Quentin Fottrell
‘Frugality will continue to reign’: Eager to save hundreds of dollars, Americans flock to one type of product A new report from the Conference Board tracks three distinct trendsA new report from the Conference Board tracks three distinct trends.
7:05 a.m. March 31, 2021 - By Ciara Linnane
UPDATE: Fauci says vaccines are offering protection against new, more infectious COVID variantsDr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases and President Joe Biden's chief medical officer, said Wednesday the vaccines that have received emergency use authorization to treat COVID-19 are protecting against new, more infectious variants of the virus. Speaking at a regular press briefing, Fauci said there are two mechanisms protecting against variants; a high titer of antibody and a T-Cell response. Fauci cited a paper that was published on Tuesday, and showed that individuals who have been vaccinated have a T Cell memory response against variants and not just against the virus they have been vaccinated against. "In their study of recovered COVID-19 patients, the researchers determined that SARS-CoV-2-specific CD8+ T-cell responses remained largely intact and could recognize virtually all mutations in the variants studied," which was written by a research team led by NIAID's Andrew Redd, Ph.D., and included scientists from Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health and the Immunomics-focused company, ImmunoScape. "While larger studies are needed, the researchers note that their findings suggest that the T cell response in convalescent individuals, and most likely in vaccinees, are largely not affected by the mutations found in these three variants, and should offer protection against emerging variants," said the paper. Fauci also said the blood clotting issue that has been reported in some cases of people who have been dosed with the vaccine developed by AstraZeneca PLC and Oxford University are at the same level as in the general population. The White House coronavirus team reiterated that they are accelerating the nation's vaccine drive and are now expecting that 90% of American adults will be eligible for a vaccine by April 19, ahead of an earlier target of early May. "We're facing an accelerating threat and we're accelerating the response even more," said Andy Slavitt, the White House's senior advisor for the COVID-19 response. President Joe Biden is asking of governors, mayors and local leaders in return that they maintain or reinstate face mask mandates, he said.
4:51 p.m. March 17, 2021 - By Meera Jagannathan
‘We can get through this’: Struggling with your mental health during the pandemic? Try these tips and resources A year into the pandemic, one in five U.S. adults say they’re experiencing high levels of psychological distressA year into the pandemic, one in five U.S. adults say they’re experiencing high levels of psychological distress.
10:40 a.m. Jan. 28, 2021 - Barrons.com
Health Care Solutions | The Wealth GapHealth disparities have become more acute amid the Covid-19 crisis. Daniel E. Dawes, J.D., director of Satcher Health Leadership Institute at the Morehouse School of Medicine, and Dr. Leana Wen, emergency physician and public health professor at George Washington University, take a look at potential solutions.
7:50 a.m. Jan. 21, 2021 - By Ciara Linnane
Biden signs flurry of orders to tackle pandemic that has now cost more than 407,000 American lives Fauci addresses board of World Health Organization with promise that U.S. will join international response to crisisThe global case tally for the coronavirus-borne illness COVID-19 edged above 97 million on Thursday with the U.S. accounting for 24 million of those cases, as President Joe Biden wasted no time in implementing his plan to address a crisis that has caused the loss of more than 407,000 American lives.
Browse topics:
Link to MarketWatch's Slice.